[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rtms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rtms":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,65,96,122,150,175,195,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100645335","phase-4-biomarker-guided-antidepressant-selection-100645335",false,"NCT07680140","Biomarker-Guided Antidepressant Selection","Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression","BioSelect","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Adults of all genders aged 18-70 at the time of screening\n3. Diagnosis of Major Depressive Disorder (by DSM-5 criteria)\n4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \\>= 14 or as determined by a study clinician)\n5. Failed at least 1 prior trial of standard first-line treatment for MDD per the modified Antidepressant Treatment History form, the Maudsley Staging Method, and APA Practice Guidelines (e.g., SSRI, SNRI, CBT) OR initiated and discontinued a trial of a first-line treatment for MDD (e.g. could not tolerate side effects, etc.)\n6. Not currently taking antidepressants OR on a stable dose of antidepressant for at least 1month prior to screening and plans to remain off antidepressants OR on this stable dose for the duration of participation\n7. Current medication regimen is compatible with safe participation in the trial in the assessment of a study clinician\n8. Access to psychiatric care before, during, and after completion of the study\n9. For females of reproductive potential: agreement to use effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation\n10. Proficiency in English sufficient to complete assessments and follow study procedure instructions\n11. Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n1. Imminent risk of suicide\n2. Presence of primary psychiatric diagnosis other than MDD (e.g., post-traumatic stress disorder, obsessive-compulsive disorder, MDD with psychotic features, primary psychotic illness, bipolar I or II disorder)\n3. History of epilepsy or a history of seizures that would influence the participant's risk for TMS-evoked seizures; history of any condition \u002F concurrent medication that could notably lower seizure threshold in the estimation of a study clinician\n4. Met criteria for any clinically significant substance use disorder (by DSM-V criteria) with active substance misuse in the 6 months prior to screening\n5. Lifetime history of PCP\u002Fketamine abuse\n6. History or presence of significant neurological disorder that may be contributing to current depressive symptoms in the judgment of a study clinician (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy)\n7. Presence of medical contraindications to ketamine, including liver function tests \\> 2.5x normal limit, recent myocardial infarction, congestive heart failure \\> stage 2, angina pectoris, clinically significant bradycardia or tachycardia at the baseline assessment, or uncontrolled hypertension\n8. MRI contraindication, including presence of ferromagnetic foreign metal bodies or implants, implanted or conductive ferromagnetic objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), and ferromagnetic permanent make-up that may undergo heating in an MRI scanner\n9. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation\n10. Abnormal bloodwork that may be contributing to depressive symptoms in the estimation of a study clinician (e.g. indicators of clinically significant hypothyroidism, kidney failure, liver failure, etc.)\n11. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures","ALL","18 Years","70 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.\n\nThis study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.",[28,29,30,31,32],"Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)","rTMS","Ketamine","fMRI","NOT_YET_RECRUITING","2026-06-25",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":22},"2026-07",{"date":41,"type":22},"2028-12",{"name":43,"class":44},"Weill Medical College of Cornell University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":45},"100645239","phase-4-neuromodulation-of-mood-switch-circuitry-in-bipolar-disorder-100645239","NCT07680153","Neuromodulation of Mood Switch Circuitry in Bipolar Disorder","CircuitBD","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Adults of all genders aged 18-70 at the time of screening.\n3. Diagnosis of Bipolar Disorder (by DSM-V criteria)\n4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \\>= 14 or as determined by expert clinician).\n5. Not currently taking medications for BD OR on a stable dose of medication for at least 1 month prior to screening and plans to remain off medications OR on this stable dose for the duration of participation.\n6. Access to psychiatric care before, during, and after completion of the study.\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.\n8. Proficiency in English sufficient to complete assessments and follow study procedure instructions.\n9. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n1. Imminent risk of suicide.\n2. Presence of a primary DSM-5 diagnosis other than bipolar disorder (BD-I or BD-II), or a current comorbid psychiatric disorder that, in the opinion of the investigators, would confound outcome assessment or interfere with safe participation.\n3. History of seizures or any condition \u002F concurrent medication that could notably lower seizure threshold.\n4. Met criteria for any significant substance use disorder (by DSM-V criteria) in the 6 months prior to screening.\n5. History or presence of significant neurological disorder (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy).\n6. History or presence of significant heart condition (e.g., recent myocardial infarction, congestive heart failure \\> stage 2, angina pectoris, bradycardia or tachycardia at the baseline assessment, uncontrolled hypertension).\n7. MRI contraindication, including presence of foreign metal bodies or implants, implanted or conductive objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), permanent make-up.\n8. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation.\n9. Abnormal bloodwork for electrolytes, thyroid, or liver function.\n10. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures.",{"count":54,"type":22},62,[25],"This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD.\n\nInvestigators in this study will use a technique called repetitive transcranial magnetic stimulation, or rTMS. It uses non-invasive magnetic pulses delivered to the scalp to stimulate specific areas of the brain. rTMS is already used to treat depression, and investigators are now studying whether it can be made even more effective for people with bipolar disorder by precisely targeting an individualized brain region for each participant. Participants in this study will receive two courses of rTMS, one active and one placebo (called \"sham\"), in a randomized order so investigators can directly compare the effects. Before treatment, investigators will use brain scans (MRI) to create a personalized map of each participant's brain activity. This lets investigators identify the exact stimulation target most likely to influence the brain circuits involved in BD mood shifts. Investigators will track mood symptoms closely throughout the study to measure what changes.\n\nInvestigators believe that depression in BD is partly driven by disrupted communication between two brain regions involved in processing what feels important or rewarding. Investigators want to find out whether rTMS can restore that communication and whether doing so leads to measurable improvements in depression.",[58,59,30,32],"Bipolar Disorder (BD)","Bipolar 1 Depression",{"date":36,"type":37},{"date":39,"type":22},{"date":63,"type":22},"2031-12",{"name":43,"class":44},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100608046","precision-brain-stimulation-to-reduce-cannabis-craving-in-schizophrenia-100608046","NCT07196462","Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia","Inclusion Criteria for Psychosis Participants:\n\n* Age between 18-65 years\n* Diagnosis of a psychotic disorder according to DSM-5 criteria and confirmed by SCID\n* Current cannabis use of at least 2\u002F10 on a Visual Analog Scale\n* Current cannabis use (confirmed by urine cannabis testing)\n* Must be able to read, speak and understand English\n* Must be judged by study staff to be capable of completing the study procedures\n* Participants will be in stable outpatient psychiatric treatment and psychiatrically stable with no recent (within the past 30 days) psychiatric hospitalizations or changes in their psychiatric medication regimens.\n\nInclusion Criteria for Healthy Controls:\n\n\\- All of the above except for participants will not have a diagnosis of a psychotic disorder nor a first-degree relative with a psychotic disorder.\n\nExclusion Criteria for ALL participants:\n\n* DSM-5 intellectual disability\n* Substance use disorder (other than cannabis or nicotine) within the past three months\n* Positive urine drug screen for illicit substance use that can increase seizure risk (cocaine, benzodiazepines, amphetamine, methamphetamine)\n* Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions\n* History of head trauma resulting in any loss of consciousness (\\>15 minutes) or neurological sequelae\n* Current history of poorly controlled headaches including chronic medication for migraine prevention\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)\n* Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD\n* All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant or planning to become pregnant will not be enrolled in the study\n* Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures.\n* Any changes in medications or hospitalizations within the past 30 days.\n* Participants who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit\n\nThese exclusion criteria strictly follow all recommended guidelines as endorsed by the International Federation of Clinical Neurophysiology and the International Society for Transcranial Stimulation.",true,"65 Years",{"count":74,"type":22},100,[76],"NA","The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder.\n\nThis is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis.\n\nAim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100).\n\nAim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100).\n\nAs an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.",[79,80,81,30],"Cannabis Use","SCHIZOPHRENIA","Psychosis",[83,84,30,85],"cannabis use","schizophrenia","brain stimulation","RECRUITING","2026-05-28",{"date":89,"type":37},"2026-06-02",{"date":91,"type":37},"2026-01-15",{"date":93,"type":22},"2027-12-31",{"name":95,"class":44},"Vanderbilt University Medical Center",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100596852","rtms-for-tobacco-use-in-veterans-100596852","NCT07050862","rTMS for Tobacco Use in Veterans","Circuity-guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Tobacco Use in Veterans: A Comparison of Insula-rTMS and Prefrontal-rTMS","Inclusion Criteria:\n\n* Veteran\n* Males and females between the ages of 18 and 70\n* Individuals who smoke 10 or more cigarettes per day and have a CO level \\> 10 ppm indicative of recent smoking\n* Those who have not received substance abuse treatment within the previous 30 days\n* Those who have been stable on psychotropic medications for at least three months\n* For females, those who test non-pregnant and use adequate birth control\n* Those who are willing to provide informed consent\n* Those who can comply with protocol requirements and likely complete all study procedures\n* Those who are motivated to quit smoking (based on responses of \"very likely\" or \"somewhat likely\" in the motivation questionnaire\n\nExclusion Criteria:\n\n* Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria\n* Contraindications to MRI (e.g., metal in the skull, orbital or intracranial cavity, or claustrophobia)\n* Contraindications to rTMS (history of a seizure or epilepsy)\n* A history of autoimmune, endocrine, viral, or vascular disorders affecting the brain\n* History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment\n* Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea\n* Major Axis I disorders diagnosed according to DSM-V criteria, such as bipolar affective disorder, schizophrenia, dementia, or major depression\n\n  * Regarding the Veteran population, we will enroll smokers who have PTSD\n* Current use of other forms of nicotine delivery, such as nicotine patches or electronic cigarettes\n* Currently prescribed bupropion and\u002For varenicline",{"count":104,"type":22},56,[76],"Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation, US FDA-approved for smoking cessation. In this protocol, the investigators propose comparing the two rTMS protocols (standard TMS vs. precision TMS) to find a better treatment parameter for smoking cessation in Veterans. Identifying an efficacious rTMS protocol would benefit Veterans who want to quit smoking.",[108,30],"Tabacco Use Disorder",[110,111],"Tabacco","substance abuse","2026-04-02",{"date":114,"type":37},"2026-04-08",{"date":116,"type":22},"2026-07-01",{"date":118,"type":22},"2030-08-31",{"name":120,"class":121},"VA Office of Research and Development","FED",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":45},"100617268","repetitive-transcranial-magnetic-stimulation-in-frontotemporal-lobar-degeneration-100617268","NCT07316413","Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration","FTLD_rTMS","Inclusion Criteria:\n\n* diagnosis of FTLD (bvFTD, avPPA, svPPA, CBS, or PSP)\n* global CDR plus NACC FTLD ≤ 1\n\nExclusion Criteria:\n\n* presence of cerebrovascular disease, hydrocephalus, intracranial masses identified by MRI, history of head trauma, serious medical conditions unrelated to FTLD, history of epilepsy, and presence of electronic (e.g., pacemaker) or metallic implants in the head.",{"count":130,"type":22},120,[76],"The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of repetitive transcranial magnetic stimulation (rTMS) in patients with frontotemporal dementia (FTLD) or in asymptomatic persons at risk of FTLD (i.e., persons familiar with FTLD patients).\n\nrTMS is a non-invasive brain stimulation technique, and has demonstrated the ability to modulate neuronal activity by applying high-frequency magnetic fields to the surface of the skull. rTMS offers a potentially effective means to influence neural networks involved in the pathogenesis of neurodegenerative diseases, with benefits that could extend beyond symptomatic relief. Its safety has been widely documented in a variety of clinical conditions, making it an ideal candidate for application in neurodegenerative diseases.\n\nIn the present study, participants will undergo the following procedures: (i) clinical and neuropsychological assessment, (ii) TMS, and (iii) blood sampling. The occurrence of adverse events will be monitored throughout the duration of the study.\n\nThe study is structured in two phases. In the first phase, double-blind, randomised and placebo-controlled, participants will be randomised into two groups: group 1, participants will receive real rTMS for 2 weeks; and group 2, placebo rTMS for 2 weeks. In the second, open-label phase, after 10 weeks, both group 1 and group 2 participants will receive real rTMS for 2 weeks. Each participant will receive a total of 4 weeks of intervention (4 weeks of real stimulation in group 1, or 2 weeks of real stimulation and 2 weeks of placebo stimulation in group 2), with 5 sessions per week (Monday to Friday) lasting approximately 30 minutes each.\n\nVisits will take place at the beginning of the study (T00) and after 2 weeks (T02, end of the first phase), 12 weeks (T12, beginning of the second phase), 14 weeks (T14, end of the second phase), 24 weeks (T24, follow-up). During each visit, participants underwent the following procedures: (i) clinical and neuropsychological assessment, (ii) blood sampling, and (iii) TMS. Specific biomarker analyses will be performed on the blood samples to study the pathophysiological mechanisms of the disease and the effect of the experimental intervention.",[134,135,136,137,138,139,30,140],"FTLD","FTD","bvFTD","PPA","PSP","Cortical Basal Syndrome (CBS)","Theta Burst Stimulation","2025-12-18",{"date":143,"type":37},"2026-01-05",{"date":145,"type":37},"2025-02-13",{"date":147,"type":22},"2029-02-01",{"name":149,"class":44},"Università degli Studi di Brescia",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":45},"100601123","the-effectiveness-of-rtms-on-improving-food-craving-and-weight-control-in-adults-without-serious-mental-illness-100601123","NCT07106398","The Effectiveness of rTMS on Improving Food Craving and Weight Control in Adults Without Serious Mental Illness","Inclusion Criteria:\n\n* Healthy adults\n* Aged between 18-65\n* Self-reported food craving or weight control issues\n\nExclusion Criteria:\n\n* People with serious mental illness\n* Severe neurological conditions\n* Contraindications for rTMS\n* People on weight-reduction medications",{"count":157,"type":22},30,[76],"Department of Psychiatry \\| Li Ka Shing Faculty of Medicine\n\nThe University of Hong Kong\n\nThe Effectiveness of rTMS on Improving Food Cravings and Weight Control\n\nin Adults without Serious Mental Illness\n\nIntroduction\n\nThe investigators would like to invite participants to participate in an observational study on the efficacy of using magnetic fields to improve food cravings and weight control in adults without serious mental illness.\n\nThe research leader is Dr. Cheng Pak Wing, Assistant Professor, Department of Psychiatry, Queen Mary Hospital\u002FHKU Li Ka Shing Faculty of Medicine.\n\nPlease read the following information carefully. If necessary, participants can discuss it with relatives, friends or doctors. If anything is unclear, or if participants would like more information, please ask us. Please carefully consider whether participants are willing to participate in this research.\n\nResearch Purpose\n\nFood cravings are a common experience that can significantly impact an individual's mental and physical health. These intense desires for specific foods often lead to overconsumption of unhealthy foods, contributing to obesity, poor nutritional intake, and associated health conditions. Understanding the neural mechanisms behind food cravings is crucial for developing effective interventions to manage them.\n\nrTMS is a non-invasive brain stimulation technique that uses magnetic fields to modulate neural activity in targeted brain regions. Over the years, rTMS has shown promise in treating various mental health conditions, including depression, obsessive-compulsive disorder (OCD) and eating disorders.\n\nResearch Methods\n\nParticipants\n\nHealthy adults aged 18-65 with self-reported food cravings or weight control issues.\n\nTreatment protocol\n\nSix sessions of rTMS using the EXOMIND™ device, administered once or twice a week.\n\nEach session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds.\n\nThe target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in the research centre with medical staff supported.\n\nA checklist of potential adverse effects from TMS administration will be referenced from existing literature to monitor tolerability and adverse events during each session. Blood pressure and heart rate will be recorded at the beginning and end of each session.\n\nAssessment\n\nParticipants will be assessed at three time points: baseline (pre-intervention), post-intervention, and four weeks post-intervention.\n\nAssessments: Food Cravings Questionnaire-Trait (FCQ-T), Perceived Stress Scale (PSS), Patient Health Questionnaire-9 (PHQ-9), and BMI.\n\nDemographics: Age, gender, years of education, place of birth, marital status, number of children, financial condition, household income, family history of eating problems will be collected upon study entry. Medical history in relation to mental illnesses and medications will also be assessed.",[161,30],"Food Cravings",[163,164,165],"rtms","food cravings","healthy adults","2025-08-06",{"date":168,"type":37},"2025-08-11",{"date":170,"type":37},"2025-07-04",{"date":172,"type":22},"2028-06-27",{"name":174,"class":44},"The University of Hong Kong",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100601122","the-effectiveness-of-repetitive-transcranial-magnetic-stimulation-rtms-on-improving-sleep-quality-in-adults-without-serious-mental-illness-100601122","NCT07106385","The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental Illness","Inclusion Criteria:\n\n* Healthy adults\n* Aged between 18-65\n* Self-reported sleep complaints\n\nExclusion Criteria:\n\n* Serious mental illness other than primary insomnia\n* Severe neurological conditions\n* Contraindications for rTMS.",{"count":157,"type":22},[76],"The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on\n\nImproving Sleep Quality in Adults Without Serious Mental Illness\n\nIntroduction\n\nThe investigators would like to invite participants to participate in a study on the efficacy of using magnetic fields to improve sleep quality in adults with no serious mental illness.\n\nThe research leader is Dr. Cheng Pak Wing, Assistant Professor, Department of Psychiatry, Queen Mary Hospital\u002F HKU Li Ka Shing Faculty of Medicine.\n\nPlease read the following information carefully. If necessary, participants can discuss with relatives, friends or doctors. If anything is unclear, or if participants would like more information, please ask us. Please carefully consider whether participants are willing to participate in this research.\n\nResearch Purpose\n\nSleep is a fundamental component of overall health and well-being, playing a crucial role in cognitive function, emotional regulation, and physical health. However, sleep complaints are common, even among otherwise healthy adults, often leading to reduced quality of life and increased health risks. The prevalence of poor sleep quality can be attributed to a variety of factors, including stress, lifestyle habits, and environmental disturbances.\n\nrTMS is a non-invasive brain stimulation technique that uses magnetic fields to modulate neural activity in targeted brain regions. Over the years, rTMS has shown promise in treating various mental health conditions, including depression, obsessive-compulsive disorder (OCD) and clinical insomnia.\n\nResearch Methods\n\nParticipants\n\nHealthy adults aged 18-65 with self-reported sleep complaints.\n\nTreatment protocol\n\nSix sessions of rTMS using the EXOMIND™ device, administered once or twice a week.\n\nEach session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds.\n\nThe target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in the research centre with medical staff supported.\n\nA checklist of potential adverse effects from TMS administration will be referenced from existing literature to monitor tolerability and adverse events during each session. Blood pressure and heart rate will be recorded at the beginning and end of each session.\n\nAssessment\n\nParticipants will be assessed at three time points: baseline (pre-intervention), post-intervention, and four weeks post-intervention.\n\nAssessments: Pittsburgh Sleep Quality Index (PSQI), Perceived Stress Scale (PSS), Patient Health Questionnaire-9 (PHQ-9), and home sleep monitoring device.\n\nDemographics: age, gender, years of education, place of birth, marital status, number of children, financial condition, household income, family history of sleep difficulties will be collected upon study entry. Medical history in relation to mental illnesses and medications will also be assessed.",[185,186],"Rtms","Sleep",[163,188,189],"sleep","health adults",{"date":168,"type":37},{"date":170,"type":37},{"date":193,"type":22},"2027-10-31",{"name":174,"class":44},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":214,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":45},"100589888","effects-of-repetitive-transcranial-magnetic-stimulations-in-patients-with-amphetamine-use-disorders-100589888","NCT06960265","Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders","A Pilot Study for the Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Amphetamine Use Disorders: Clinical Outcomes, Near InfraRed Spectroscopy, and Biomarkers","Inclusion Criteria:\n\n* Age ≥20 years.\n* Meeting DSM-5 criteria for substance use disorder made by a specialist in addiction psychiatry.\n* Fluency in Chinese.\n* Willingness and ability to comply with study requirements.\n* Good physical health determined by complete physical examination, and laboratory tests.\n* Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.\n* Trained psychiatrists will assess eligible patients using the structured clinical interview for the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) to determine the presence of any psychotic disorder.\n\nExclusion Criteria:\n\n* Evidence of an uncontrolled and\u002For clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.\n* Premorbid mental retardation.\n* Other major Axis-I Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnoses other than substance use disorder.\n* Pregnancy or nursing.\n* History of seizures or epilepsy.\n* History of neurological diseases or traumatic brain injury.\n* Suicidal attempts or risks during screening or study period.\n* Presence of prosthesis devices, e.g. pace-makers, cochlear prosthesis, neuro- stimulators, magnetic cochlear prosthesis, intraocular metallic fragments.","20 Years",{"count":204,"type":22},20,[76],"Amphetamine Use Disorder (AUD) is a major public health issue in Taiwan, where it is the most commonly abused illegal drug. There are currently no effective approved medications to treat it, which makes finding new treatment options urgent. Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation method, has shown promise in reducing cravings and drug use in people with addiction, but its effects on AUD are not well studied.\n\nTo explore this, the investigators plan to conduct a double-blind, sham-controlled study with 20 people diagnosed with AUD. Half will receive real rTMS treatment, and half will receive a placebo-like sham treatment. The treatment targets a specific brain area (the left dorsolateral prefrontal cortex) and will be given 10 times over two weeks.\n\nThe investigators will assess the effectiveness of rTMS by tracking drug cravings, urine test results, and side effects with follow-up over 12 weeks. The investigators also include brain imaging using near-infrared spectroscopy (NIRS) after the treatment.\n\nThe study aims to better understand how rTMS might help reduce amphetamine cravings and improve outcomes, potentially leading to new treatment options for AUD.",[208,209,210,211,212,30,213],"Amphetamine Use Disorders","Amphetamine Use Disorder","Amphetamine Dependence","Amphetamine Abuse","NIRS","rTMS Stimulation",[215,163,212],"amphetamine","2025-04-28",{"date":218,"type":37},"2025-05-07",{"date":220,"type":22},"2025-05-15",{"date":222,"type":22},"2025-12-31",{"name":224,"class":44},"TsaoTun Psychiatric Center, Department of Health, Taiwan",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":45},"100516932","effect-of-itbs-on-children-with-adhd-100516932","NCT06010966","Effect of iTBS on Children With ADHD","Effect of Intermittent TBS on Children With ADHD","Inclusion Criteria:\n\n* Clinical diagnosis of ADHD in accordance with DSM-V;\n* Age 6-12 years old, regardless of gender\n* Right-handed\n* Han nationality or born in the Han nationality Ghetto\n* The course of the disease is greater than 6 months\n* Webster children's intelligence ≥ 70\n* The patient's guardian agrees and signs an informed consent form.\n\nExclusion Criteria:\n\n* Concomitant mental disorders such as anxiety and depression;\n* Widespread developmental disorders and other neurological developmental related disorders;\n* Complication with other important organ diseases such as heart and lungs;\n* Suffering from diseases such as epilepsy and tic disorder;\n* Individuals who cannot tolerate rTMS treatment or cannot cooperate with treatment.\n* Patients taking psychoactive drugs, antipsychotics, antidepressants, or mood stabilizers 3 months prior to enrollment or during rTMS treatment; In addition to the minimum effective therapeutic dose of Tomoxetine (1.2-1.4 mg • kg\u002Fday), there has been systematic use of first-line ADHD drugs in clinical practice Webster's intelligence\\\u003C70\n* Implantation of metal and electronic components in the body (excluding the oral cavity), such as pacemakers;","6 Years","12 Years",{"count":235,"type":22},54,[76],"Attention Deficit\u002FHyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by persistent symptoms of attention deficit and\u002For hyperactivity\u002Fimpulsivity . Currently, the first line drugs for treating ADHD are central stimulants such as Tomoxetine and Guanfaxine. However, there is a risk of drug abuse and misuse, which often affects sleep and appetite, only 50% of patients can fully tolerate. This project uses the iTBS stimulation on weekends, children with ADHD finish scale evaluation, magnetic resonance imaging analysis, and cognitive function before and after stimulation, This study explores its therapeutic effect on attention deficit in children and adolescents with ADHD.",[239,30],"ADHD","2023-12-06",{"date":242,"type":37},"2023-12-13",{"date":244,"type":37},"2023-09-01",{"date":246,"type":22},"2026-07-31",{"name":248,"class":44},"First Affiliated Hospital of Zhejiang University"]